TCRγ4δ1-engineered αβT cells exhibit effective antitumor activity

Area of Science:

• Immunology
• Cancer Biology
• Gene Therapy

Background:

• Adoptive T-cell transfer (ATC) therapy utilizes T cell engineering with tumor-specific T cell receptors (TCRs) for cancer treatment.
• Peripheral blood-derived αβT cells are a key component in developing effective cancer immunotherapies.

Purpose of the Study:

• To develop a novel strategy for redirecting peripheral blood-derived αβT cells against tumors using TCRγ4δ1 gene transduction.
• To evaluate the anti-tumor efficacy, proliferation, cytokine production, and safety of TCRγ4δ1-engineered αβT cells.

Main Methods:

• Lentiviral transduction was used to introduce TCRγ4δ1 genes into αβT cells.
• In vitro and in vivo assays were performed to assess cytotoxicity, proliferation, cytokine production, and potential autoimmunity.
• Tumor-bearing mouse models were used to evaluate the in vivo anti-tumor effects.

Main Results:

• TCRγ4δ1 genes were successfully transduced into approximately 36% of αβT cells.
• Engineered αβT cells demonstrated potent TCRγδ-dependent cytotoxicity against various tumor cells via the perforin-granzyme pathway.
• Adoptive transfer of engineered T cells significantly suppressed tumor growth in vivo without targeting normal cells.

Conclusions:

• TCRγ4δ1 gene transduction offers a novel approach for engineering αβT cells for cancer immunotherapy.
• TCRγ4δ1-engineered αβT cells show significant potential for gene therapy and adoptive T-cell transfer in cancer treatment.